Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Memorial Day Pre-Sale: Train 2 injectors for the price of 1! Aesthetic Medicine Symposium (June 5-8, 2026) in Scottsdale, AZ. Limited spots available!

Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification

Memorial Day Pre-Sale: Train 2 injectors for the price of 1! 
Botox training at the Aesthetic Medicine Symposium in sunny Scottsdale, AZ.
(June 5-8, 2026). Limited spots available!

April 2026 Aesthetic Medicine Update: Treating the Whole Patient

April 2026 Aesthetic Medicine Update: Treating the Whole Patient

April’s clinical and business signals point in the same direction: the practices growing most consistently right now are those expanding their definition of who their patient is. From menopausal skin protocols to GLP-1 consult frameworks and wellness integration strategies, this month’s update covers what to implement now and what to keep on your radar.

Read More »
Billing statement on a clipboard with a stethoscope, beside a tablet showing health insurance and the TAPAM logo.

The Financial Architecture of a Profitable Aesthetic Practice

Building a profitable aesthetic practice requires more than clinical skill — it requires understanding the unit economics, patient lifetime value, and retention strategies that separate high-performing practices from the rest. This article breaks down the financial architecture behind sustainable aesthetic medicine, from service mix margins to evidence-based retention data.

Read More »
YY001 & Recombinant Botulinum Toxins: A Clinical Overview

YY001 & Recombinant Botulinum Toxins: A Clinical Overview

A recombinant botulinum toxin type A called YY001 recently completed a Phase III trial showing favorable efficacy and safety results compared to onabotulinumtoxinA for glabellar lines. While the product is not available in the United States, understanding how recombinant toxins differ from traditional formulations helps aesthetic providers evaluate emerging data and marketing claims.

Read More »
Relfydess Is Coming: What Aesthetic Providers Should Do Now

Relfydess Is Coming: What Aesthetic Providers Should Do Now

Relfydess (relabotulinumtoxinA) is a ready-to-use, complex-free liquid neurotoxin with Phase 3 data supporting rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients. Here’s what aesthetic providers need to know about its clinical profile—and how to prepare their practice before adding it to the menu.

Read More »

Treating Décolletage Wrinkles: A 2026 Clinical Guide

The FDA approval of RADIESSE for décolletage wrinkle treatment marks the first time a biostimulatory filler has been cleared for both facial and body indications in the United States. This 2026 clinical guide covers every injectable and non-injectable option available — from SKINVIVE and Sculptra to fractional lasers and RF microneedling — with guidance on patient selection and combination protocols.

Read More »